Monograph
M01AX05 - Glucosamine |
Not porphyrinogenic |
NP |
Rationale
No CYP-dependent metabolism.
Chemical description
Relatively small and water-soluble molecule (MW 179)
Therapeutic characteristics
Endogenous substance that possibly works by a positiv influence on cartilage metabolism. Common adverse reactions that can be mistaken for porphyria symptoms are dyspepsia, stomach ache, diarrhoea, constipation, nausea.
Hepatic exposure
Significant
Metabolism and pharmacokinetics
Metabolized mainly by the hexosamine-system and thereby independent of the cytopchrome P-450 system (1).
Preclinical data
None
Personal communication
None
Published experience
None
IPNet drug reports
Uneventful use reported in 28 patients with acute porphyria.
Similar drugs
References
# | Citation details | PMID |
---|---|---|
* | Summary of Product Characteristics | |
1. | 1) SPC glucosamine (updated: 2007-12-20).
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025